X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

    Once More, M&As In Biotechechnology Industry Are Thriving

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

    Once More, M&As In Biotechechnology Industry Are Thriving

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Tillotts Pharma AG opens new affiliate in Italy

Content Team by Content Team
26th October 2021
in Drug Development, Manufacturing, News
Tillotts Pharma AG opens new affiliate in Italy

Tillotts Pharma AG, part of the Japanese Zeria Group, today announced the opening of its Italian affiliate, which will be led by Fabrizio Savoldi as Managing Director Tillotts Italy. The achievement of this exciting new milestone is expected to further accelerate Tillotts’ European footprint and tap the full potential of its innovative portfolio in one of the company’s important markets. In November 2020, Tillotts expanded its portfolio with the acquisition of Dificlir™, a narrow spectrum antibiotic that fills a gap in the treatment of patients suffering from Clostridioides difficile infections (CDI). This acquisition laid the foundation for direct presence on various European markets.

Today Tillotts operates in 65 countries through its own affiliates and distributors. The new Italian affiliate provides strategic access to one of the top five European markets ensuring the groups continued success now also on the Italian market. By founding its own affiliate, the company shows its commitment to continuously invest in an organisation that is able to directly promote their products in the country and deliver high-quality service for health care professionals and patients. “Italy is an important key market for Tillotts and we are very proud of positioning ourselves there. The new organisation will enable us to intensify our close collaboration with local health care professionals, offer state-of-the-art training services, and bring additional growth for Tillotts in Europe”, says Fabrizio Savoldi, who joined Tillotts Italy recently as Managing Director.

Fabrizio Savoldi has more than 18 years’ experience in Pharmaceuticals and brings considerable operational and management experience to Tillotts serving in various leadership positions on local and global levels. He holds a graduation in Pharmacy, a Master in Business Administration from SDA Bocconi in Milan, and recently acquired a certificate in Global Management at Insead.

“With the acquisition of Dificlir™, we have taken an important strategic step to expand our product portfolio beyond classical gastroenterology and with that being able to enter into new European markets, such as Italy and others more in the very near future”, says Mattias Norrman, Chief Operations Officer at Tillotts. “This offers new opportunities to provide patients and health care professionals with not only gold standard products but also educational services in our therapeutic areas throughout Europe with own local presence. At the same time, we are convinced that our innovative treatment solutions and our comprehensive portfolio will fuel the future development of Tillotts.”

By opening the affiliate, the group can focus on the further commercialisation of its portfolio. The new Italian team will concentrate on medical and marketing activities for the recently acquired product Dificlir™ and existing core products such as EntocirTM. EntocirTM, a first-line anti-inflammatory drug based on the active ingredient Budesonide, is indicated for the induction and maintenance of remission of mild to moderate ileocaecal Crohn’s disease.

Previous Post

Moderna Announces MOU to Supply up to 110 Million Doses of Its COVID-19 Vaccine to the African Union

Next Post

Aptar Pharma Enters into Partnership with Stallergenes Greer to Develop Novel Digital Health Ecosystem for Allergen Immunotherapy Treatment

Related Posts

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022
FDA Approvals

Food And Drug Administration User Fee Has Been Reauthorized

3rd November 2022
Clinical Trials

Cancer Clinical Trials Get A Brand New Platform In Melbourne

3rd November 2022
Next Post
Aptar Pharma Enters into Partnership with Stallergenes Greer to Develop Novel Digital Health Ecosystem for Allergen Immunotherapy Treatment

Aptar Pharma Enters into Partnership with Stallergenes Greer to Develop Novel Digital Health Ecosystem for Allergen Immunotherapy Treatment

Latest News

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022
FDA Approvals

Food And Drug Administration User Fee Has Been Reauthorized

3rd November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In